Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis

November 1, 2019 Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma

Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
News
shutterstock_273326141

Transactions in the pharma sector: Through the EU merger review looking-glass

October 31, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing mergers, mergers and acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
Feature
abbvie_0

AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population

October 31, 2019 Research and Development AbbVie, Rinvoq, pharma

AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
News
index

Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes

October 31, 2019 Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure

Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
News
shutterstock_212432119

Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

October 31, 2019 Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
News
david_eatwell

Genmab’s Executive VP and CFO to retire in 2020

October 31, 2019 Research and Development Genmab, appointment, pharma

David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …
News
pharmafocus_november_2019_front_cover

The November 2019 issue of Pharmafocus is available to read for free online now!

October 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The latest monthly edition of Pharmafocus, the November issue, is available to read for free online now!
News

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019 Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
News

FDA slams brakes on trial for world’s most expensive drug following safety concerns in children

October 30, 2019 Research and Development FDA, Novartis, Zolgensma, pharma

The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …
News

Expanded EU label for Benlyta now covers paediatric lupus patients

October 30, 2019 Research and Development, Sales and Marketing Benlyta, Europe, GSK, Lupus, pharma

GlaxoSmithKline is celebrating the news that the European Commission has chosen to approve an expansion to the label of its …
News

European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis

October 30, 2019 Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma

Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …
News
gsk_boronia_australia

GSK’s tuberculosis vaccine shows efficacy over three years in HIV negative patients

October 29, 2019 Manufacturing and Production, Research and Development GSK, IAVI, Vaccine, pharma, tuberculosis

Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the …
News

AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

October 29, 2019 Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
News
shutterstock_339308225

Deeper patient insights for stronger patient outcomes

October 28, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing eyeforpharma, pharma

Patient insights are crucial. As you already know, they are the key to the creation of successful, targeted programmes and …
News
gilead-sciences

Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

October 28, 2019 Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025